Function-based Consortium for IBD
Inflammatory Bowel Disease
Pre-clinicalActive
Key Facts
About PharmaBiome
PharmaBiome is a pre-clinical stage biotech pioneering a function-based approach to microbiome therapeutics. Originating from ETH Zurich, its platform focuses on engineering consortia of bacteria based on their metabolic interactions to restore core functions lost in dysbiosis. The company has established key R&D collaborations with industry partners like Ferring and Roquette and is advancing its science towards targeted therapies for inflammatory and other microbiome-linked conditions.
View full company profileTherapeutic Areas
Other Inflammatory Bowel Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Entyvio (vedolizumab) | Takeda Pharmaceutical | Commercial |
| Galapagos Collaboration | Scipher Medicine | Discovery/Pre-clinical |
| TEV-‘574 (TL1A Inhibitor) | Teva | Phase 3 |
| IBD Subclassification | Bio-Me | Research |
| Anti-iRhom2 antibodies | SciRhom | Pre-clinical |
| IBD Multi-omics Dataset | Ovation.io | Commercial |